Contact CFFC

Oct

Clinical Trial Alerts – October 2017

Cystic Fibrosis Foundation distributed the following clinical trial updates during the month of October. Click the trial title to get more details.

The following alerts were distributed on October 13th:

Cohorts 1 and 2 of a study to evaluate inhaled QBW276 in adults with CF

Status: Enrolling

Description: This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. This study will look at the safety and tolerability of the inhaled drug QBW276 as well as how the body processes the drug.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 40 to 100%

Number of Visits: 6

Length of Participation: 14 days

ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT02566044

Cohort 3 of a study to evaluate inhaled QBW276 in adults with CF

Status: Enrolling

Description: This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. This study will look at the safety, effectiveness, and tolerability of the inhaled drug QBW276.

Age: 18 Years and Older

Mutation: Two Copies F508del

Fev1% Predicted: 40 to 100%

Number of Visits: 15

Length of Participation: 3 months

ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT02566044


Comments are closed.